The Effect of Vicia Faba Hydrolysate Supplementation on Muscle Strength Recovery
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-45
SponsorPepsiCo Global R&D
About this trial
To investigate the effect of Vicia faba protein concentrate, a protein derived from Fava bean extract, on delayed onset muscle soreness (DOMS). Participants receive either 2.4g/day of PeptiStrong® supplement capsules or placebo capsules for 14 days until a strenuous exercise session. For the last 3 days, 2/3 of them stay on the same treatment and 1/3 of them switch from placebo to PeptiStrong®.
Eligibility criteria
Qualifiers
Males and females 18 - 45 years of age.
Willing to fast overnight on the 4 testing occasions.
Participants agree to abstain from taking additional supplements throughout the testing period, with particular emphasis placed upon protein-based products (e.g., whey or casein based protein powders; animal derived protein hydrolysates; natural supplements constituted of vegetative protein hydrolysates from rice, fava bean, pea, carrot, spirulina, broccoli, potatoes; marine derived secondary metabolite products or protein hydrolysates including Omega-3 capsules or DHA).
Moderately active (exercise 3-5 days per week)
Disqualifiers
Individuals that are glucose-6-phosphate-dehydrogenase deficient. The test product in this study contains fava bean extract which may produce favism in genetically susceptible individuals.
Alcohol or drug abuse in the past year.3. Testosterone or estrogen supplementation (not including women on oral contraceptives)
Pregnant or nursing or planning to become pregnant.
Participation in any other clinical trial in the past 30 days. Participation in any PepsiCo trial in the past 6 months
Trial design
Treatments tested in this trial
- Placebo control capsules
- PeptiStrong® supplement capsules with same appearance as placebo capsules
- PeptiStrong® supplement capsules following muscle damaging exercise on Day 14
Treatment groups
76 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov